Tecentriq Raises Hope of New Mesothelioma Clinical Trial

The FDA recently approved immunotherapy drug Tecentriq (atezolizumab) for certain bladder and non-small cell lung cancers, raising hopes for a mesothelioma-specific clinical trial in 2017. Tecentriq, a product of Genentech Oncology, is following the path of Keytruda (pembrolizumab) and Opdivo (nivolumab) as drugs that target a specific protein blocking a body’s immune system from attacking cancer cells. The U.S. Food and Drug Administration sanctioned Keytruda and Opdivo earlier for non-small cell lung cancer, and those drugs are working their way through the clinical trial process for the treatment of mesothelioma. Mesothelioma patients already are using both drugs sporadically and successfully through the FDA’s Patient Access or Compassionate Use programs. Most medical specialists agree these immunotherapy drugs have the potential to change the current standard-of-care regimen used for mesothelioma and many other cancers today. “Immunotherapy is a game changer,” said Dr. Drew Pardoll, director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy in Baltimore. “We don’t think there is a single cancer out there that the patient’s own immune system can’t beat.” Unleashing the Immune System with Tecentriq All three of these drugs target the PD-L1 or PD-1 proteins that prevent the immune system from destroying the cancers. These proteins are expressed typically in about half of mesothelioma patients diagnosed. The rates...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: atezolizumab bladder cancer drug for mesothelioma immunotherapy for mesothelioma keytruda for mesothelioma opdivo for mesothelioma tecentriq Source Type: news

Related Links:

Publication date: Available online 2 April 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Stefan Schmidt, Annett Linge, Marianne Großer, Fabian Lohaus, Volker Gudziol, Alexander Nowak, Ingeborg Tinhofer, Volker Budach, Ali Sak, Martin Stuschke, Panagiotis Balermpas, Claus Rödel, Henning Schäfer, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Ute Ganswindt, Claus Belka, Steffi Pigorsch, Stephanie E. Combs
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Authors: Peng Y, Wei Q, He Y, Xie Q, Liang Y, Zhang L, Xia Y, Li Y, Chen W, Zhao J, Chai J Abstract Introduction: Hepatocellular carcinoma (HCC) is an aggressive tumor type which results in poor prognosis. ALBI and Child-Pugh score have been widely applied for predicting prognosis in patients with liver diseases. We conducted a systematic review to compare the prognostic ability of ALBI versus Child-Pugh in HCC patients.Areas covered: PubMed, EMBASE and Cochrane Library were explored. The data were extracted from every study. Studies investigating HCC patients and comparing the predicting ability between ALBI and C...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
CONCLUSIONS: Our findings support the protective effect a normal weight against advanced adenomas. Reduction of BMI value should be pursued in healthy programs. PMID: 32233893 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Conclusion: There is a slightly increasing trend in the occurrence of esophageal perforations. Contemporary treatment is less invasive with similar results. Patients treated in high-volume hospitals have better prognosis. PMID: 32233883 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More than one fifth of patients who are treated for gynecologic malignancies experience financial toxicity, results of a single-center study suggest.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Results of a systematic review and meta-analysis support a possible role for osimertinib in the management of non-small-cell lung cancer (NSCLC) patients with intracranial metastatic disease, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Authors: Montemurro F, Nuzzolese I, Ponzone R Abstract Introduction: The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field.Areas covered: Herein, the authors cover neoadjuvant chemotherapy with or without biologics in triple-negative and HER2-positive operable breast cancer with a focus on rates of complete pathological remission (pCR) in the breast and axilla. The impact of the CREATE X and KATERINE randomi...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
One of the biggest challenges of this unsettling time is the isolation we feel as we’re separated from friends and family, all the people for whom we care most deeply. But just being alone is only part of the difficulty. Our sense of remoteness is intensified by a pall of unease we can’t define: Loss and sorrow are also in the air. We fear losing—or we may have already lost—people we love. And when we work up the courage to look beyond our individual personal spheres, we see that many people who have made our world better, in big and small ways, have vanished before we were ready to let them go. But...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature remembrance Source Type: news
Publication date: Available online 2 April 2020Source: Saudi Pharmaceutical JournalAuthor(s): Md. Salman Akhtar, Naseem Akhter, Mohammad Zeeshan Najm, SVS Deo, NK Shukla, Shaia Saleh R. Almalki, Raed A. Alharbi, Abdulmajeed Abdulghani A. Sindi, Abdulmohsen Alruwetei, Abrar Ahmad, Syed Akhtar Husain
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Dr Mark Kris discusses the profound effect that the wait time between cancer being diagnosed and treatment being initiated has on both patients and physicians.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More News: Asbestosis | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Hematology | Immunotherapy | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Study